FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Marco Bua

Research Profile

Disorders

Chemicals & Drugs

Procedures

Concepts & Ideas

Physiology

Co-author Network

Publications

TOP 3
Pratap Neelakantan; Stephen O'Brien; Christos Paliompeis; Alistair Reid; K Rezvani; Lihui Wang; Marco Bua; Richard Clark; Gareth Gerrard; John Goldman; Claire Lucas; Philippa May; Dragana Milojkovic; David Marin
Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies.
Dragana Milojkovic; Alistair Reid; K Rezvani; Richard Szydlo; Jane F Apperley; Marco Bua; Letizia Foroni; Gareth Gerrard; John Goldman; Amr R Ibrahim; David Marin
Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients.
David Marin; Dragana Milojkovic; S O'Brien; R Sergeant; K Stringaris; H de Lavallade; S Ahmad; A Alsuliman; Jane F Apperley; Marco Bua; R Clark; N Cooper; J Davis; Letizia Foroni; I H Gabriel; John M Goldman; C Hedgley; A Khoder; Jamshid Sorouri Khorashad; K Rezvani
KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Marco Bua (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Pratap Neelakantan; Stephen O'Brien; Christos Paliompeis; Alistair Reid; K Rezvani; Lihui Wang; Marco Bua; Richard Clark; Gareth Gerrard; John Goldman; Claire Lucas; Philippa May; Dragana Milojkovic; David Marin
Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies.
Blood 2013;121(14):2739-42.
2012: Dragana Milojkovic; Alistair Reid; K Rezvani; Richard Szydlo; Jane F Apperley; Marco Bua; Letizia Foroni; Gareth Gerrard; John Goldman; Amr R Ibrahim; David Marin
Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients.
Blood 2012;119(8):1838-43.
2012: David Marin; Dragana Milojkovic; S O'Brien; R Sergeant; K Stringaris; H de Lavallade; S Ahmad; A Alsuliman; Jane F Apperley; Marco Bua; R Clark; N Cooper; J Davis; Letizia Foroni; I H Gabriel; John M Goldman; C Hedgley; A Khoder; Jamshid Sorouri Khorashad; K Rezvani
KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib.
Leukemia 2012;26(2):296-302.
2012: David Marin; Dragana Milojkovic; Christos Paliompeis; Jiri Pavlu; Alistair Reid; K Rezvani; Richard Szydlo; Lihui Wang; Jane F Apperley; Marco Bua; Richard E Clark; Gareth Gerrard; John M Goldman; Amr R Ibrahim; Claire Lucas; Letizia Foroni
Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(3):232-8.
2011: Amr R Ibrahim; Lina Eliasson; Jane F Apperley; Dragana Milojkovic; Marco Bua; Richard Szydlo; François-Xavier Mahon; Kasia Kozlowski; Christos Paliompeis; Letizia Foroni; Jamshid Sorouri Khorashad; Alex Bazeos; Mathieu Molimard; Alistair Reid; K Rezvani; Gareth Gerrard; John Goldman; David Marin
Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy.
Blood 2011;117(14):3733-6.
2011: H W Auner; L Mazzarella; L Cook; Richard Szydlo; F Saltarelli; Jiri Pavlu; Marco Bua; Chrissy Giles; Jane F Apperley; Amin Rahemtulla
High rate of stem cell mobilization failure after thalidomide and oral cyclophosphamide induction therapy for multiple myeloma.
Bone marrow transplantation 2011;46(3):364-7.
2010: Amr R Ibrahim; Christos Paliompeis; Marco Bua; Dragana Milojkovic; Richard Szydlo; Jamshid Sorouri Khorashad; Letizia Foroni; Alistair Reid; Hugues de Lavallade; K Rezvani; Francesco Dazzi; Jane F Apperley; John M Goldman; David Marin
Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy.
Blood 2010;116(25):5497-500.
2010: Aya Kuwabara; Anna Babb; Amr Ibrahim; Dragana Milojkovic; Jane Apperley; Marco Bua; Alistair Reid; Letizia Foroni; K Rezvani; John Goldman; David Marin
Poor outcome after reintroduction of imatinib in patients with chronic myeloid leukemia who interrupt therapy on account of pregnancy without having achieved an optimal response.
Blood 2010;116(6):1014-6.
2010: David Marin; Alexandra Bazeos; François-Xavier Mahon; Lina Eliasson; Dragana Milojkovic; Marco Bua; Jane F Apperley; Richard Szydlo; Ritti Desai; Kasia Kozlowski; Christos Paliompeis; Victoria Latham; Letizia Foroni; Mathieu Molimard; Alistair Reid; K Rezvani; Hugues de Lavallade; Cristina Guallar; John Goldman; Jamshid Sorouri Khorashad
Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(14):2381-8.
2010: Dragana Milojkovic; Emma Nicholson; Jane F Apperley; Tessa L Holyoake; Pat Shepherd; Mark W Drummond; Richard Szydlo; Marco Bua; Letizia Foroni; Alistair Reid; Jamshid Sorouri Khorashad; Hugues de Lavallade; K Rezvani; Christos Paliompeis; John M Goldman; David Marin
Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia.
Haematologica 2010;95(2):224-31.
2009: David Marin; Jamshid Sorouri Khorashad; Letizia Foroni; Dragana Milojkovic; Richard Szydlo; Alistair G Reid; K Rezvani; Marco Bua; John M Goldman; Jane F Apperley
Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse?
British journal of haematology 2009;145(3):373-5.
2008: David Marin; Dragana Milojkovic; Eduardo Olavarria; Jamshid Sorouri Khorashad; Hugues de Lavallade; Alistair G Reid; Letizia Foroni; K Rezvani; Marco Bua; Francesco Dazzi; Jiri Pavlu; Matthias Klammer; Jaspal Kaeda; John M Goldman; Jane F Apperley
European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor.
Blood 2008;112(12):4437-44.
2008: Jamshid Sorouri Khorashad; Hugues de Lavallade; Jane F Apperley; Dragana Milojkovic; Alistair G Reid; Marco Bua; Richard Szydlo; Eduardo Olavarria; Jaspal Kaeda; John M Goldman; David Marin
Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(29):4806-13.
2008: Hugues de Lavallade; Jane F Apperley; Jamshid Sorouri Khorashad; Dragana Milojkovic; Alistair G Reid; Marco Bua; Richard Szydlo; Eduardo Olavarria; Jaspal Kaeda; John M Goldman; David Marin
Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(20):3358-63.
2007: M P Simula; Sarah Marktel; Claudio Fozza; Jaspal Kaeda; Richard Szydlo; Elisabet Nadal; Marco Bua; Amin Rahemtulla; Edward Kanfer; David Marin; Eduardo Olavarria; John M Goldman; Jane F Apperley; Francesco Dazzi
Response to donor lymphocyte infusions for chronic myeloid leukemia is dose-dependent: the importance of escalating the cell dose to maximize therapeutic efficacy.
Leukemia 2007;21(5):943-8.
2005: David Marin; Jaspal Kaeda; Catharina Andreasson; Sue M Saunders; Marco Bua; Eduardo Olavarria; John M Goldman; Jane F Apperley
Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib.
Cancer 2005;103(9):1850-5.
2005: David Marin; Jaspal Kaeda; Richard Szydlo; S Saunders; A Fleming; J Howard; Catharina Andreasson; Marco Bua; Eduardo Olavarria; Amin Rahemtulla; Francesco Dazzi; Edward Kanfer; John M Goldman; Jane F Apperley
Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse.
Leukemia 2005;19(4):507-12.
2003: David Marin; Sarah Marktel; Richard Szydlo; John P Klein; Marco Bua; Nicola Foot; Eduardo Olavarria; Pat Shepherd; Edward Kanfer; John M Goldman; Jane F Apperley
Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa.
Lancet 2003;362(9384):617-9.
2003: David Marin; Sarah Marktel; Marco Bua; Richard Szydlo; A Franceschino; I Nathan; Nicola Foot; Charles Crawley; T Na Nakorn; Eduardo Olavarria; Anne Lennard; A Neylon; S G O'Brien; John M Goldman; Jane F Apperley
Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa.
Leukemia 2003;17(8):1448-53.
2003: Sarah Marktel; David Marin; Nicola Foot; Richard Szydlo; Marco Bua; Anastasios Karadimitris; Valeria A S De Melo; Paul Kotzampaltiris; Francesco Dazzi; Amin Rahemtulla; Eduardo Olavarria; Jane F Apperley; John M Goldman
Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression.
Haematologica 2003;88(3):260-7.
2003: David Marin; Sarah Marktel; Nicola Foot; Marco Bua; John M Goldman; Jane F Apperley
Granulocyte colony-stimulating factor reverses cytopenia and may permit cytogenetic responses in patients with chronic myeloid leukemia treated with imatinib mesylate.
Haematologica 2003;88(2):227-9.
2002: David Marin; Sarah Marktel; Marco Bua; Lorraine Armstrong; John M Goldman; Jane F Apperley; Eduardo Olavarria
The use of imatinib (STI571) in chronic myelod leukemia: some practical considerations.
Haematologica 2002;87(9):979-88.
2002: Jyoti Wadhwa; Richard Szydlo; Jane F Apperley; Andrew Chase; Marco Bua; David Marin; Eduardo Olavarria; Edward Kanfer; John M Goldman
Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia.
Blood 2002;99(7):2304-9.